Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
8,836
archived clinical trials in
Leukemia

Donor Stem Cell Transplant in Treating Young Patients With Acute Myeloid Leukemia With Monosomy 7, -5/5q-, High FLT3-ITD AR, or Refractory or Relapsed Acute Myelogenous Leukemia
Killer Immunoglobulin-like Receptor (KIR) Incompatible Unrelated Donor Hematopoietic Cell Transplantation (SCT) for AML With Monosomy 7, -5/5q-, High FLT3-ITD AR, or Refractory and Relapsed Acute Myelogenous Leukemia (AML) in Children: A Children's Oncology Group (COG) Study
Status: Enrolling
Updated:  4/18/2016
CCOP - Nevada Cancer Research Foundation
mi
from
Las Vegas, NV
Donor Stem Cell Transplant in Treating Young Patients With Acute Myeloid Leukemia With Monosomy 7, -5/5q-, High FLT3-ITD AR, or Refractory or Relapsed Acute Myelogenous Leukemia
Killer Immunoglobulin-like Receptor (KIR) Incompatible Unrelated Donor Hematopoietic Cell Transplantation (SCT) for AML With Monosomy 7, -5/5q-, High FLT3-ITD AR, or Refractory and Relapsed Acute Myelogenous Leukemia (AML) in Children: A Children's Oncology Group (COG) Study
Status: Enrolling
Updated: 4/18/2016
CCOP - Nevada Cancer Research Foundation
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Donor Stem Cell Transplant in Treating Young Patients With Acute Myeloid Leukemia With Monosomy 7, -5/5q-, High FLT3-ITD AR, or Refractory or Relapsed Acute Myelogenous Leukemia
Killer Immunoglobulin-like Receptor (KIR) Incompatible Unrelated Donor Hematopoietic Cell Transplantation (SCT) for AML With Monosomy 7, -5/5q-, High FLT3-ITD AR, or Refractory and Relapsed Acute Myelogenous Leukemia (AML) in Children: A Children's Oncology Group (COG) Study
Status: Enrolling
Updated:  4/18/2016
Penn State Children's Hospital
mi
from
Hershey, PA
Donor Stem Cell Transplant in Treating Young Patients With Acute Myeloid Leukemia With Monosomy 7, -5/5q-, High FLT3-ITD AR, or Refractory or Relapsed Acute Myelogenous Leukemia
Killer Immunoglobulin-like Receptor (KIR) Incompatible Unrelated Donor Hematopoietic Cell Transplantation (SCT) for AML With Monosomy 7, -5/5q-, High FLT3-ITD AR, or Refractory and Relapsed Acute Myelogenous Leukemia (AML) in Children: A Children's Oncology Group (COG) Study
Status: Enrolling
Updated: 4/18/2016
Penn State Children's Hospital
mi
from
Hershey, PA
Click here to add this to my saved trials
Donor Stem Cell Transplant in Treating Young Patients With Acute Myeloid Leukemia With Monosomy 7, -5/5q-, High FLT3-ITD AR, or Refractory or Relapsed Acute Myelogenous Leukemia
Killer Immunoglobulin-like Receptor (KIR) Incompatible Unrelated Donor Hematopoietic Cell Transplantation (SCT) for AML With Monosomy 7, -5/5q-, High FLT3-ITD AR, or Refractory and Relapsed Acute Myelogenous Leukemia (AML) in Children: A Children's Oncology Group (COG) Study
Status: Enrolling
Updated:  4/18/2016
Cook Children's Medical Center - Fort Worth
mi
from
Fort Worth, TX
Donor Stem Cell Transplant in Treating Young Patients With Acute Myeloid Leukemia With Monosomy 7, -5/5q-, High FLT3-ITD AR, or Refractory or Relapsed Acute Myelogenous Leukemia
Killer Immunoglobulin-like Receptor (KIR) Incompatible Unrelated Donor Hematopoietic Cell Transplantation (SCT) for AML With Monosomy 7, -5/5q-, High FLT3-ITD AR, or Refractory and Relapsed Acute Myelogenous Leukemia (AML) in Children: A Children's Oncology Group (COG) Study
Status: Enrolling
Updated: 4/18/2016
Cook Children's Medical Center - Fort Worth
mi
from
Fort Worth, TX
Click here to add this to my saved trials
Donor Stem Cell Transplant in Treating Young Patients With Acute Myeloid Leukemia With Monosomy 7, -5/5q-, High FLT3-ITD AR, or Refractory or Relapsed Acute Myelogenous Leukemia
Killer Immunoglobulin-like Receptor (KIR) Incompatible Unrelated Donor Hematopoietic Cell Transplantation (SCT) for AML With Monosomy 7, -5/5q-, High FLT3-ITD AR, or Refractory and Relapsed Acute Myelogenous Leukemia (AML) in Children: A Children's Oncology Group (COG) Study
Status: Enrolling
Updated:  4/18/2016
CCOP - Scott and White Hospital
mi
from
Temple, TX
Donor Stem Cell Transplant in Treating Young Patients With Acute Myeloid Leukemia With Monosomy 7, -5/5q-, High FLT3-ITD AR, or Refractory or Relapsed Acute Myelogenous Leukemia
Killer Immunoglobulin-like Receptor (KIR) Incompatible Unrelated Donor Hematopoietic Cell Transplantation (SCT) for AML With Monosomy 7, -5/5q-, High FLT3-ITD AR, or Refractory and Relapsed Acute Myelogenous Leukemia (AML) in Children: A Children's Oncology Group (COG) Study
Status: Enrolling
Updated: 4/18/2016
CCOP - Scott and White Hospital
mi
from
Temple, TX
Click here to add this to my saved trials
Donor Stem Cell Transplant in Treating Young Patients With Acute Myeloid Leukemia With Monosomy 7, -5/5q-, High FLT3-ITD AR, or Refractory or Relapsed Acute Myelogenous Leukemia
Killer Immunoglobulin-like Receptor (KIR) Incompatible Unrelated Donor Hematopoietic Cell Transplantation (SCT) for AML With Monosomy 7, -5/5q-, High FLT3-ITD AR, or Refractory and Relapsed Acute Myelogenous Leukemia (AML) in Children: A Children's Oncology Group (COG) Study
Status: Enrolling
Updated:  4/18/2016
Children's and Women's Hospital of British Columbia
mi
from
Vancouver,
Donor Stem Cell Transplant in Treating Young Patients With Acute Myeloid Leukemia With Monosomy 7, -5/5q-, High FLT3-ITD AR, or Refractory or Relapsed Acute Myelogenous Leukemia
Killer Immunoglobulin-like Receptor (KIR) Incompatible Unrelated Donor Hematopoietic Cell Transplantation (SCT) for AML With Monosomy 7, -5/5q-, High FLT3-ITD AR, or Refractory and Relapsed Acute Myelogenous Leukemia (AML) in Children: A Children's Oncology Group (COG) Study
Status: Enrolling
Updated: 4/18/2016
Children's and Women's Hospital of British Columbia
mi
from
Vancouver,
Click here to add this to my saved trials
Haploidentical Transplant With NK Cell Infusion for Pediatric Acute Leukemia and Solid Tumors
Reduced Intensity Haploidentical Transplantation With NK Cell Infusion for Pediatric Acute Leukemia and High Risk Solid Tumors, BMT06407
Status: Enrolling
Updated:  4/20/2016
Kenneth DeSantes., MD
mi
from
Madison, WI
Haploidentical Transplant With NK Cell Infusion for Pediatric Acute Leukemia and Solid Tumors
Reduced Intensity Haploidentical Transplantation With NK Cell Infusion for Pediatric Acute Leukemia and High Risk Solid Tumors, BMT06407
Status: Enrolling
Updated: 4/20/2016
Kenneth DeSantes., MD
mi
from
Madison, WI
Click here to add this to my saved trials
Ponatinib - Frontline for Chronic Myeloid Leukemia (CML) in Accelerated Phase (AP)
Ponatinib as Initial Therapy for Patients With Chronic Myeloid Leukemia in Accelerated Phase
Status: Enrolling
Updated:  5/13/2016
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Ponatinib - Frontline for Chronic Myeloid Leukemia (CML) in Accelerated Phase (AP)
Ponatinib as Initial Therapy for Patients With Chronic Myeloid Leukemia in Accelerated Phase
Status: Enrolling
Updated: 5/13/2016
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Sirolimus in Combination With MEC in High Risk Myeloid Leukemias
A Prospective Single Institution Pilot Study Evaluating the Pharmacokinetics of Sirolimus in Combination With MEC (Mitoxantrone + Etoposide + Cytarabine) in Patients With High Risk Leukemias
Status: Enrolling
Updated:  6/7/2016
University of Pennsylvania:Abramson Cancer Center
mi
from
Philadelphia, PA
Sirolimus in Combination With MEC in High Risk Myeloid Leukemias
A Prospective Single Institution Pilot Study Evaluating the Pharmacokinetics of Sirolimus in Combination With MEC (Mitoxantrone + Etoposide + Cytarabine) in Patients With High Risk Leukemias
Status: Enrolling
Updated: 6/7/2016
University of Pennsylvania:Abramson Cancer Center
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Carfilzomib in Patients With Relapsed Acute Myeloid or Acute Lymphoblastic Leukemia
A Phase I Trial of Carfilzomib in Adult Patients With Relapsed Acute Myeloid and Acute Lymphoblastic Leukemia
Status: Enrolling
Updated:  6/13/2016
Washington University School of Medicine
mi
from
St. Louis, MO
Carfilzomib in Patients With Relapsed Acute Myeloid or Acute Lymphoblastic Leukemia
A Phase I Trial of Carfilzomib in Adult Patients With Relapsed Acute Myeloid and Acute Lymphoblastic Leukemia
Status: Enrolling
Updated: 6/13/2016
Washington University School of Medicine
mi
from
St. Louis, MO
Click here to add this to my saved trials
Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Acute Myeloid Leukemia in Second Remission
AUTOLOGOUS STEM CELL TRANSPLANTATION FOR ACUTE MYELOID LEUKEMIA IN SECOND REMISSION: A PHASE II STUDY
Status: Enrolling
Updated:  6/27/2016
UCSF Cancer Center and Cancer Research Institute
mi
from
San Francisco, CA
Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Acute Myeloid Leukemia in Second Remission
AUTOLOGOUS STEM CELL TRANSPLANTATION FOR ACUTE MYELOID LEUKEMIA IN SECOND REMISSION: A PHASE II STUDY
Status: Enrolling
Updated: 6/27/2016
UCSF Cancer Center and Cancer Research Institute
mi
from
San Francisco, CA
Click here to add this to my saved trials
Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Acute Myeloid Leukemia in Second Remission
AUTOLOGOUS STEM CELL TRANSPLANTATION FOR ACUTE MYELOID LEUKEMIA IN SECOND REMISSION: A PHASE II STUDY
Status: Enrolling
Updated:  6/27/2016
Marlene & Stewart Greenebaum Cancer Center, University of Maryland
mi
from
Baltimore, MD
Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Acute Myeloid Leukemia in Second Remission
AUTOLOGOUS STEM CELL TRANSPLANTATION FOR ACUTE MYELOID LEUKEMIA IN SECOND REMISSION: A PHASE II STUDY
Status: Enrolling
Updated: 6/27/2016
Marlene & Stewart Greenebaum Cancer Center, University of Maryland
mi
from
Baltimore, MD
Click here to add this to my saved trials
Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Acute Myeloid Leukemia in Second Remission
AUTOLOGOUS STEM CELL TRANSPLANTATION FOR ACUTE MYELOID LEUKEMIA IN SECOND REMISSION: A PHASE II STUDY
Status: Enrolling
Updated:  6/27/2016
St. Joseph's Hospital and Medical Center
mi
from
Paterson, NJ
Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Acute Myeloid Leukemia in Second Remission
AUTOLOGOUS STEM CELL TRANSPLANTATION FOR ACUTE MYELOID LEUKEMIA IN SECOND REMISSION: A PHASE II STUDY
Status: Enrolling
Updated: 6/27/2016
St. Joseph's Hospital and Medical Center
mi
from
Paterson, NJ
Click here to add this to my saved trials
Motivational Counseling in Preventing Smoking Relapse After Pregnancy in Pregnant Women Who Quit Smoking During Pregnancy
Smoking Relapse Prevention Among Postpartum Women
Status: Enrolling
Updated:  6/27/2016
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Motivational Counseling in Preventing Smoking Relapse After Pregnancy in Pregnant Women Who Quit Smoking During Pregnancy
Smoking Relapse Prevention Among Postpartum Women
Status: Enrolling
Updated: 6/27/2016
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Cancer
Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation For Patients With Disease Relapse Or Myelodysplasia After Prior Autologous Transplantation
Status: Enrolling
Updated:  6/30/2016
Rebecca and John Moores UCSD Cancer Center
mi
from
La Jolla, CA
Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Cancer
Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation For Patients With Disease Relapse Or Myelodysplasia After Prior Autologous Transplantation
Status: Enrolling
Updated: 6/30/2016
Rebecca and John Moores UCSD Cancer Center
mi
from
La Jolla, CA
Click here to add this to my saved trials
Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Cancer
Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation For Patients With Disease Relapse Or Myelodysplasia After Prior Autologous Transplantation
Status: Enrolling
Updated:  6/30/2016
Beebe Medical Center
mi
from
Lewes, DE
Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Cancer
Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation For Patients With Disease Relapse Or Myelodysplasia After Prior Autologous Transplantation
Status: Enrolling
Updated: 6/30/2016
Beebe Medical Center
mi
from
Lewes, DE
Click here to add this to my saved trials
Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Cancer
Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation For Patients With Disease Relapse Or Myelodysplasia After Prior Autologous Transplantation
Status: Enrolling
Updated:  6/30/2016
CCOP - Christiana Care Health Services
mi
from
Newark, DE
Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Cancer
Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation For Patients With Disease Relapse Or Myelodysplasia After Prior Autologous Transplantation
Status: Enrolling
Updated: 6/30/2016
CCOP - Christiana Care Health Services
mi
from
Newark, DE
Click here to add this to my saved trials
Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Cancer
Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation For Patients With Disease Relapse Or Myelodysplasia After Prior Autologous Transplantation
Status: Enrolling
Updated:  6/30/2016
St. Francis Hospital
mi
from
Wilmington, DE
Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Cancer
Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation For Patients With Disease Relapse Or Myelodysplasia After Prior Autologous Transplantation
Status: Enrolling
Updated: 6/30/2016
St. Francis Hospital
mi
from
Wilmington, DE
Click here to add this to my saved trials
Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Cancer
Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation For Patients With Disease Relapse Or Myelodysplasia After Prior Autologous Transplantation
Status: Enrolling
Updated:  6/30/2016
Union Hospital Cancer Center at Union Hospital
mi
from
Elkton MD, MD
Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Cancer
Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation For Patients With Disease Relapse Or Myelodysplasia After Prior Autologous Transplantation
Status: Enrolling
Updated: 6/30/2016
Union Hospital Cancer Center at Union Hospital
mi
from
Elkton MD, MD
Click here to add this to my saved trials
Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Cancer
Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation For Patients With Disease Relapse Or Myelodysplasia After Prior Autologous Transplantation
Status: Enrolling
Updated:  6/30/2016
Siteman Cancer Center at Barnes-Jewish Hospital
mi
from
St Louis, MO
Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Cancer
Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation For Patients With Disease Relapse Or Myelodysplasia After Prior Autologous Transplantation
Status: Enrolling
Updated: 6/30/2016
Siteman Cancer Center at Barnes-Jewish Hospital
mi
from
St Louis, MO
Click here to add this to my saved trials
Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Cancer
Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation For Patients With Disease Relapse Or Myelodysplasia After Prior Autologous Transplantation
Status: Enrolling
Updated:  6/30/2016
Cancer Institute of New Jersey at the Cooper University Hospital - Voorhees
mi
from
Voorhees, NJ
Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Cancer
Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation For Patients With Disease Relapse Or Myelodysplasia After Prior Autologous Transplantation
Status: Enrolling
Updated: 6/30/2016
Cancer Institute of New Jersey at the Cooper University Hospital - Voorhees
mi
from
Voorhees, NJ
Click here to add this to my saved trials
Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Cancer
Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation For Patients With Disease Relapse Or Myelodysplasia After Prior Autologous Transplantation
Status: Enrolling
Updated:  6/30/2016
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Cancer
Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation For Patients With Disease Relapse Or Myelodysplasia After Prior Autologous Transplantation
Status: Enrolling
Updated: 6/30/2016
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Click here to add this to my saved trials
Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Cancer
Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation For Patients With Disease Relapse Or Myelodysplasia After Prior Autologous Transplantation
Status: Enrolling
Updated:  6/30/2016
Wake Forest University Comprehensive Cancer Center
mi
from
Winston-Salem, NC
Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Cancer
Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation For Patients With Disease Relapse Or Myelodysplasia After Prior Autologous Transplantation
Status: Enrolling
Updated: 6/30/2016
Wake Forest University Comprehensive Cancer Center
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Cancer
Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation For Patients With Disease Relapse Or Myelodysplasia After Prior Autologous Transplantation
Status: Enrolling
Updated:  6/30/2016
Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University
mi
from
Columbus, OH
Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Cancer
Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation For Patients With Disease Relapse Or Myelodysplasia After Prior Autologous Transplantation
Status: Enrolling
Updated: 6/30/2016
Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University
mi
from
Columbus, OH
Click here to add this to my saved trials
Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Cancer
Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation For Patients With Disease Relapse Or Myelodysplasia After Prior Autologous Transplantation
Status: Enrolling
Updated:  6/30/2016
Western Pennsylvania Cancer Institute at Western Pennsylvania Hospital
mi
from
Pittsburgh, PA
Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Cancer
Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation For Patients With Disease Relapse Or Myelodysplasia After Prior Autologous Transplantation
Status: Enrolling
Updated: 6/30/2016
Western Pennsylvania Cancer Institute at Western Pennsylvania Hospital
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Cancer
Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation For Patients With Disease Relapse Or Myelodysplasia After Prior Autologous Transplantation
Status: Enrolling
Updated:  6/30/2016
Massey Cancer Center, Virginia Commonwealth University
mi
from
Richmond, VA
Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Cancer
Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation For Patients With Disease Relapse Or Myelodysplasia After Prior Autologous Transplantation
Status: Enrolling
Updated: 6/30/2016
Massey Cancer Center, Virginia Commonwealth University
mi
from
Richmond, VA
Click here to add this to my saved trials
Relationship Between Natural Killer Cells' Ability to Kill Leukemia Cells and the Outcome of Patients With Acute Myeloid Leukemia Previously Treated With Interleukin-2
A Study of the Relationship Between Natural Killer Cell Recognition and Lysis of Autologous Leukemic Blasts and Clinical Outcome of Acute Myeloid Leukemia Patients Treated With Interleukin-2: A CALGB Leukemia Tissue Bank Project
Status: Enrolling
Updated:  7/12/2016
Kinston Medical Specialists
mi
from
Kinston, NC
Relationship Between Natural Killer Cells' Ability to Kill Leukemia Cells and the Outcome of Patients With Acute Myeloid Leukemia Previously Treated With Interleukin-2
A Study of the Relationship Between Natural Killer Cell Recognition and Lysis of Autologous Leukemic Blasts and Clinical Outcome of Acute Myeloid Leukemia Patients Treated With Interleukin-2: A CALGB Leukemia Tissue Bank Project
Status: Enrolling
Updated: 7/12/2016
Kinston Medical Specialists
mi
from
Kinston, NC
Click here to add this to my saved trials
Relationship Between Natural Killer Cells' Ability to Kill Leukemia Cells and the Outcome of Patients With Acute Myeloid Leukemia Previously Treated With Interleukin-2
A Study of the Relationship Between Natural Killer Cell Recognition and Lysis of Autologous Leukemic Blasts and Clinical Outcome of Acute Myeloid Leukemia Patients Treated With Interleukin-2: A CALGB Leukemia Tissue Bank Project
Status: Enrolling
Updated:  7/12/2016
Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
Relationship Between Natural Killer Cells' Ability to Kill Leukemia Cells and the Outcome of Patients With Acute Myeloid Leukemia Previously Treated With Interleukin-2
A Study of the Relationship Between Natural Killer Cell Recognition and Lysis of Autologous Leukemic Blasts and Clinical Outcome of Acute Myeloid Leukemia Patients Treated With Interleukin-2: A CALGB Leukemia Tissue Bank Project
Status: Enrolling
Updated: 7/12/2016
Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
Click here to add this to my saved trials
Omega-3 Fatty Acids in Treating Patients With Advanced Cancer Who Have Significant Weight Loss
Phase I/II Trial of Omega-3 Fatty Acids for Cancer Cachexia
Status: Enrolling
Updated:  7/12/2016
CCOP - Christiana Care Health Services
mi
from
Wilmington, DE
Omega-3 Fatty Acids in Treating Patients With Advanced Cancer Who Have Significant Weight Loss
Phase I/II Trial of Omega-3 Fatty Acids for Cancer Cachexia
Status: Enrolling
Updated: 7/12/2016
CCOP - Christiana Care Health Services
mi
from
Wilmington, DE
Click here to add this to my saved trials
Omega-3 Fatty Acids in Treating Patients With Advanced Cancer Who Have Significant Weight Loss
Phase I/II Trial of Omega-3 Fatty Acids for Cancer Cachexia
Status: Enrolling
Updated:  7/12/2016
Holden Comprehensive Cancer Center at University of Iowa
mi
from
Iowa City, IA
Omega-3 Fatty Acids in Treating Patients With Advanced Cancer Who Have Significant Weight Loss
Phase I/II Trial of Omega-3 Fatty Acids for Cancer Cachexia
Status: Enrolling
Updated: 7/12/2016
Holden Comprehensive Cancer Center at University of Iowa
mi
from
Iowa City, IA
Click here to add this to my saved trials
Omega-3 Fatty Acids in Treating Patients With Advanced Cancer Who Have Significant Weight Loss
Phase I/II Trial of Omega-3 Fatty Acids for Cancer Cachexia
Status: Enrolling
Updated:  7/12/2016
North Shore University Hospital
mi
from
Manhasset, NY
Omega-3 Fatty Acids in Treating Patients With Advanced Cancer Who Have Significant Weight Loss
Phase I/II Trial of Omega-3 Fatty Acids for Cancer Cachexia
Status: Enrolling
Updated: 7/12/2016
North Shore University Hospital
mi
from
Manhasset, NY
Click here to add this to my saved trials
Omega-3 Fatty Acids in Treating Patients With Advanced Cancer Who Have Significant Weight Loss
Phase I/II Trial of Omega-3 Fatty Acids for Cancer Cachexia
Status: Enrolling
Updated:  7/12/2016
The New York Presbyterian Hospital - Cornell Campus
mi
from
New York, NY
Omega-3 Fatty Acids in Treating Patients With Advanced Cancer Who Have Significant Weight Loss
Phase I/II Trial of Omega-3 Fatty Acids for Cancer Cachexia
Status: Enrolling
Updated: 7/12/2016
The New York Presbyterian Hospital - Cornell Campus
mi
from
New York, NY
Click here to add this to my saved trials
Omega-3 Fatty Acids in Treating Patients With Advanced Cancer Who Have Significant Weight Loss
Phase I/II Trial of Omega-3 Fatty Acids for Cancer Cachexia
Status: Enrolling
Updated:  7/12/2016
CCOP - Southeast Cancer Control Consortium
mi
from
Winston-Salem, NC
Omega-3 Fatty Acids in Treating Patients With Advanced Cancer Who Have Significant Weight Loss
Phase I/II Trial of Omega-3 Fatty Acids for Cancer Cachexia
Status: Enrolling
Updated: 7/12/2016
CCOP - Southeast Cancer Control Consortium
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Epoetin Alfa in Treating Anemia in Patients Who Are Receiving Chemotherapy
A Phase III Randomized Double-Blind Study of Erythropoietin Versus Placebo in Anemic Patients With Cancer Undergoing Chemotherapy
Status: Enrolling
Updated:  7/12/2016
CCOP - Scottsdale Oncology Program
mi
from
Scottsdale, AZ
Epoetin Alfa in Treating Anemia in Patients Who Are Receiving Chemotherapy
A Phase III Randomized Double-Blind Study of Erythropoietin Versus Placebo in Anemic Patients With Cancer Undergoing Chemotherapy
Status: Enrolling
Updated: 7/12/2016
CCOP - Scottsdale Oncology Program
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Epoetin Alfa in Treating Anemia in Patients Who Are Receiving Chemotherapy
A Phase III Randomized Double-Blind Study of Erythropoietin Versus Placebo in Anemic Patients With Cancer Undergoing Chemotherapy
Status: Enrolling
Updated:  7/12/2016
Howard University Cancer Center
mi
from
Washington,
Epoetin Alfa in Treating Anemia in Patients Who Are Receiving Chemotherapy
A Phase III Randomized Double-Blind Study of Erythropoietin Versus Placebo in Anemic Patients With Cancer Undergoing Chemotherapy
Status: Enrolling
Updated: 7/12/2016
Howard University Cancer Center
mi
from
Washington,
Click here to add this to my saved trials
Epoetin Alfa in Treating Anemia in Patients Who Are Receiving Chemotherapy
A Phase III Randomized Double-Blind Study of Erythropoietin Versus Placebo in Anemic Patients With Cancer Undergoing Chemotherapy
Status: Enrolling
Updated:  7/12/2016
CCOP - Illinois Oncology Research Association
mi
from
Peoria, IL
Epoetin Alfa in Treating Anemia in Patients Who Are Receiving Chemotherapy
A Phase III Randomized Double-Blind Study of Erythropoietin Versus Placebo in Anemic Patients With Cancer Undergoing Chemotherapy
Status: Enrolling
Updated: 7/12/2016
CCOP - Illinois Oncology Research Association
mi
from
Peoria, IL
Click here to add this to my saved trials
Epoetin Alfa in Treating Anemia in Patients Who Are Receiving Chemotherapy
A Phase III Randomized Double-Blind Study of Erythropoietin Versus Placebo in Anemic Patients With Cancer Undergoing Chemotherapy
Status: Enrolling
Updated:  7/12/2016
CCOP - Carle Cancer Center
mi
from
Urbana, IL
Epoetin Alfa in Treating Anemia in Patients Who Are Receiving Chemotherapy
A Phase III Randomized Double-Blind Study of Erythropoietin Versus Placebo in Anemic Patients With Cancer Undergoing Chemotherapy
Status: Enrolling
Updated: 7/12/2016
CCOP - Carle Cancer Center
mi
from
Urbana, IL
Click here to add this to my saved trials
Epoetin Alfa in Treating Anemia in Patients Who Are Receiving Chemotherapy
A Phase III Randomized Double-Blind Study of Erythropoietin Versus Placebo in Anemic Patients With Cancer Undergoing Chemotherapy
Status: Enrolling
Updated:  7/12/2016
CCOP - Cedar Rapids Oncology Project
mi
from
Cedar Rapids, IA
Epoetin Alfa in Treating Anemia in Patients Who Are Receiving Chemotherapy
A Phase III Randomized Double-Blind Study of Erythropoietin Versus Placebo in Anemic Patients With Cancer Undergoing Chemotherapy
Status: Enrolling
Updated: 7/12/2016
CCOP - Cedar Rapids Oncology Project
mi
from
Cedar Rapids, IA
Click here to add this to my saved trials
Epoetin Alfa in Treating Anemia in Patients Who Are Receiving Chemotherapy
A Phase III Randomized Double-Blind Study of Erythropoietin Versus Placebo in Anemic Patients With Cancer Undergoing Chemotherapy
Status: Enrolling
Updated:  7/12/2016
CCOP - Iowa Oncology Research Association
mi
from
Des Moines, IA
Epoetin Alfa in Treating Anemia in Patients Who Are Receiving Chemotherapy
A Phase III Randomized Double-Blind Study of Erythropoietin Versus Placebo in Anemic Patients With Cancer Undergoing Chemotherapy
Status: Enrolling
Updated: 7/12/2016
CCOP - Iowa Oncology Research Association
mi
from
Des Moines, IA
Click here to add this to my saved trials
Epoetin Alfa in Treating Anemia in Patients Who Are Receiving Chemotherapy
A Phase III Randomized Double-Blind Study of Erythropoietin Versus Placebo in Anemic Patients With Cancer Undergoing Chemotherapy
Status: Enrolling
Updated:  7/12/2016
Siouxland Hematology-Oncology
mi
from
Sioux City, IA
Epoetin Alfa in Treating Anemia in Patients Who Are Receiving Chemotherapy
A Phase III Randomized Double-Blind Study of Erythropoietin Versus Placebo in Anemic Patients With Cancer Undergoing Chemotherapy
Status: Enrolling
Updated: 7/12/2016
Siouxland Hematology-Oncology
mi
from
Sioux City, IA
Click here to add this to my saved trials
Epoetin Alfa in Treating Anemia in Patients Who Are Receiving Chemotherapy
A Phase III Randomized Double-Blind Study of Erythropoietin Versus Placebo in Anemic Patients With Cancer Undergoing Chemotherapy
Status: Enrolling
Updated:  7/12/2016
CCOP - Wichita
mi
from
Wichita, KA
Epoetin Alfa in Treating Anemia in Patients Who Are Receiving Chemotherapy
A Phase III Randomized Double-Blind Study of Erythropoietin Versus Placebo in Anemic Patients With Cancer Undergoing Chemotherapy
Status: Enrolling
Updated: 7/12/2016
CCOP - Wichita
mi
from
Wichita, KA
Click here to add this to my saved trials
Epoetin Alfa in Treating Anemia in Patients Who Are Receiving Chemotherapy
A Phase III Randomized Double-Blind Study of Erythropoietin Versus Placebo in Anemic Patients With Cancer Undergoing Chemotherapy
Status: Enrolling
Updated:  7/12/2016
CCOP - Ochsner
mi
from
New Orleans, LA
Epoetin Alfa in Treating Anemia in Patients Who Are Receiving Chemotherapy
A Phase III Randomized Double-Blind Study of Erythropoietin Versus Placebo in Anemic Patients With Cancer Undergoing Chemotherapy
Status: Enrolling
Updated: 7/12/2016
CCOP - Ochsner
mi
from
New Orleans, LA
Click here to add this to my saved trials
Epoetin Alfa in Treating Anemia in Patients Who Are Receiving Chemotherapy
A Phase III Randomized Double-Blind Study of Erythropoietin Versus Placebo in Anemic Patients With Cancer Undergoing Chemotherapy
Status: Enrolling
Updated:  7/12/2016
CCOP - Duluth
mi
from
Duluth, MN
Epoetin Alfa in Treating Anemia in Patients Who Are Receiving Chemotherapy
A Phase III Randomized Double-Blind Study of Erythropoietin Versus Placebo in Anemic Patients With Cancer Undergoing Chemotherapy
Status: Enrolling
Updated: 7/12/2016
CCOP - Duluth
mi
from
Duluth, MN
Click here to add this to my saved trials
Epoetin Alfa in Treating Anemia in Patients Who Are Receiving Chemotherapy
A Phase III Randomized Double-Blind Study of Erythropoietin Versus Placebo in Anemic Patients With Cancer Undergoing Chemotherapy
Status: Enrolling
Updated:  7/12/2016
Mayo Clinic Cancer Center
mi
from
Rochester, MN
Epoetin Alfa in Treating Anemia in Patients Who Are Receiving Chemotherapy
A Phase III Randomized Double-Blind Study of Erythropoietin Versus Placebo in Anemic Patients With Cancer Undergoing Chemotherapy
Status: Enrolling
Updated: 7/12/2016
Mayo Clinic Cancer Center
mi
from
Rochester, MN
Click here to add this to my saved trials
Epoetin Alfa in Treating Anemia in Patients Who Are Receiving Chemotherapy
A Phase III Randomized Double-Blind Study of Erythropoietin Versus Placebo in Anemic Patients With Cancer Undergoing Chemotherapy
Status: Enrolling
Updated:  7/12/2016
CentraCare Clinic
mi
from
Saint Cloud, MN
Epoetin Alfa in Treating Anemia in Patients Who Are Receiving Chemotherapy
A Phase III Randomized Double-Blind Study of Erythropoietin Versus Placebo in Anemic Patients With Cancer Undergoing Chemotherapy
Status: Enrolling
Updated: 7/12/2016
CentraCare Clinic
mi
from
Saint Cloud, MN
Click here to add this to my saved trials
Epoetin Alfa in Treating Anemia in Patients Who Are Receiving Chemotherapy
A Phase III Randomized Double-Blind Study of Erythropoietin Versus Placebo in Anemic Patients With Cancer Undergoing Chemotherapy
Status: Enrolling
Updated:  7/12/2016
CCOP - Missouri Valley Cancer Consortium
mi
from
Omaha, NE
Epoetin Alfa in Treating Anemia in Patients Who Are Receiving Chemotherapy
A Phase III Randomized Double-Blind Study of Erythropoietin Versus Placebo in Anemic Patients With Cancer Undergoing Chemotherapy
Status: Enrolling
Updated: 7/12/2016
CCOP - Missouri Valley Cancer Consortium
mi
from
Omaha, NE
Click here to add this to my saved trials
Epoetin Alfa in Treating Anemia in Patients Who Are Receiving Chemotherapy
A Phase III Randomized Double-Blind Study of Erythropoietin Versus Placebo in Anemic Patients With Cancer Undergoing Chemotherapy
Status: Enrolling
Updated:  7/12/2016
Medcenter One Health System
mi
from
Bismarck, ND
Epoetin Alfa in Treating Anemia in Patients Who Are Receiving Chemotherapy
A Phase III Randomized Double-Blind Study of Erythropoietin Versus Placebo in Anemic Patients With Cancer Undergoing Chemotherapy
Status: Enrolling
Updated: 7/12/2016
Medcenter One Health System
mi
from
Bismarck, ND
Click here to add this to my saved trials
Epoetin Alfa in Treating Anemia in Patients Who Are Receiving Chemotherapy
A Phase III Randomized Double-Blind Study of Erythropoietin Versus Placebo in Anemic Patients With Cancer Undergoing Chemotherapy
Status: Enrolling
Updated:  7/12/2016
CCOP - Merit Care Hospital
mi
from
Fargo, ND
Epoetin Alfa in Treating Anemia in Patients Who Are Receiving Chemotherapy
A Phase III Randomized Double-Blind Study of Erythropoietin Versus Placebo in Anemic Patients With Cancer Undergoing Chemotherapy
Status: Enrolling
Updated: 7/12/2016
CCOP - Merit Care Hospital
mi
from
Fargo, ND
Click here to add this to my saved trials
Epoetin Alfa in Treating Anemia in Patients Who Are Receiving Chemotherapy
A Phase III Randomized Double-Blind Study of Erythropoietin Versus Placebo in Anemic Patients With Cancer Undergoing Chemotherapy
Status: Enrolling
Updated:  7/12/2016
Altru Health Systems
mi
from
Grand Forks, ND
Epoetin Alfa in Treating Anemia in Patients Who Are Receiving Chemotherapy
A Phase III Randomized Double-Blind Study of Erythropoietin Versus Placebo in Anemic Patients With Cancer Undergoing Chemotherapy
Status: Enrolling
Updated: 7/12/2016
Altru Health Systems
mi
from
Grand Forks, ND
Click here to add this to my saved trials
Epoetin Alfa in Treating Anemia in Patients Who Are Receiving Chemotherapy
A Phase III Randomized Double-Blind Study of Erythropoietin Versus Placebo in Anemic Patients With Cancer Undergoing Chemotherapy
Status: Enrolling
Updated:  7/12/2016
CCOP - Toledo Community Hospital Oncology Program
mi
from
Toledo, OH
Epoetin Alfa in Treating Anemia in Patients Who Are Receiving Chemotherapy
A Phase III Randomized Double-Blind Study of Erythropoietin Versus Placebo in Anemic Patients With Cancer Undergoing Chemotherapy
Status: Enrolling
Updated: 7/12/2016
CCOP - Toledo Community Hospital Oncology Program
mi
from
Toledo, OH
Click here to add this to my saved trials
Epoetin Alfa in Treating Anemia in Patients Who Are Receiving Chemotherapy
A Phase III Randomized Double-Blind Study of Erythropoietin Versus Placebo in Anemic Patients With Cancer Undergoing Chemotherapy
Status: Enrolling
Updated:  7/12/2016
CCOP - Geisinger Clinic and Medical Center
mi
from
Danville, PA
Epoetin Alfa in Treating Anemia in Patients Who Are Receiving Chemotherapy
A Phase III Randomized Double-Blind Study of Erythropoietin Versus Placebo in Anemic Patients With Cancer Undergoing Chemotherapy
Status: Enrolling
Updated: 7/12/2016
CCOP - Geisinger Clinic and Medical Center
mi
from
Danville, PA
Click here to add this to my saved trials